Abstracts tagged "autoantigens"

Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 1524 • ACR Convergence 2025
Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
David Karp¹, Prithvi Raj¹, Changsong Zhu¹, Dajiang Liu², Duanping Liao² and Nancy Olsen³, ¹UT Southwestern Medical Center, Dallas, TX, ²Penn State College of Medicine, Hershey, PA, ³Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE, NCT03030118) was a double-blind, randomized, placebo-controlled study of hydroxychloroquine (HCQ) to prevent the development of…
Abstract Number: 1514 • ACR Convergence 2025
Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
Yan Wang¹, Lulu Cao², Mengze Xu³, Jian Lu³, Jing He¹, Fanlei Hu⁴ and Zhanguo Li⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, ³State Key Laboratory of Protein and Plant Gene Research, Center for Bioinformatics, School of Life Sciences, Peking University, Beijing, China., Beijing, Beijing, China (People's Republic), ⁴Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits profound clinical and pathogenic heterogeneity, complicating diagnosis and treatment. Identifying subtype-specific biomarkers might intrinsically link to organ involvement.Methods: Patients…
Abstract Number: 0997 • ACR Convergence 2025
Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
Olivia Pryor¹, Catalina Burbano², Nathaniel Bagge², Rutuja Kulkarni², Heather F. Jones², Livio Dukaj², Shoshana M.K. Bloom², Jackson Lirette², Rachel Lent², Prachi Dhanania², Nicole A. Ladd², Ryan Kritzer², Hana Husic², Shobitha Jillella², Candace R. Perullo², Jinyu Zhu², Teagan J. Parsons², Ira Jain², Rakshika Balasubramaniyam², Kenneth L. Jahan², Vivin Karthik², Alexander Cristofaro¹, Chandan K. Pavuluri², Jenna LaBelle², Laurie Barefoot², Shrikanta Chattopadhyay², Kim M. Cirelli², Mollie M. Jurewicz², Andrew P. Ferretti² and Cagan Gurer², ¹TScan Therapeutics, Waltham, ²TScan Therapeutics, Waltham, MA
Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
Abstract Number: 0948 • ACR Convergence 2025
Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease
Lance Peterson¹, Hannah KL De Cleene², Cheryl Lichti², David Bending³ and Kodi Ravichandran², ¹Rheumatology and Immunology, Pediatrics, Washington University School of Medicine, St. Louis, MO, ²Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ³Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, United Kingdom
Background/Purpose: Systemic lupus erythematosus is a chronic, multisystem autoimmune disease characterized by the dysregulated clearance of dying cells, which results in the release of damage-associated…
Abstract Number: 0924 • ACR Convergence 2025
Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology
Lauren Klingemann¹, Michael Duryee¹, Nozima Aripova¹, Wenxian Zhou², Hannah Johnson¹, Breanna Butler¹, Carlos Hunter¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Post-translational modifications (PTMs) of self-proteins are implicated in the pathogenesis of rheumatoid arthritis (RA). The PTMs, malondialdehyde-acetaldehyde (MAA), citrulline (CIT), and the co-modification of…
Abstract Number: 0923 • ACR Convergence 2025
Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Julia Rood¹, Stephanie Suh Kyung Yoon², Mary Heard¹, Michael Hogan², Nicola Ternette³, Edward Behrens⁴ and Laurence Eisenlohr¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Dundee, Dundee, Scotland, United Kingdom, ⁴CHOP, West Chester, PA
Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…
Abstract Number: 0921 • ACR Convergence 2025
Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Carlos Hunter¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that…
Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Zsuzsanna McMahan¹, Srinivas Puttapaka², Livia Casciola-Rosen³, Timothy Kaniecki³, Laura Gutierrez³, Su Hong MIng², Philippa Seika² and Subhash Kulkarni⁴, ¹UT Health Houston, Houston, TX, ²BIDMC/Harvard, Boston, MA, ³Johns Hopkins University, Baltimore, MD, ⁴BIDMC, Boston, MA
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
Abstract Number: 0900 • ACR Convergence 2025
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
Charlotta Preger¹, Maria Aspenberg¹, Metta Berenpas¹, Armita Dwivedi², Juliana Bordignon Draibe³, Peter Nilsson¹, Mark A. Little² and Elisa Pin¹, ¹Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ²Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ³Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…
Abstract Number: 2528 • ACR Convergence 2025
Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
Federica Bonaso¹, Zhenrui Zhang², Mahilan Guha³, Ian Doyle⁴, Jesse Akaa⁴, Grace McMahon⁵, Isha Jha⁵, Sydney Montesi⁵, Thomas Guy⁶, Guy Katz⁵, Zachary Wallace⁷, John Stone⁸, Vinay S. Mahajan⁹, Shiv Pillai¹⁰ and Cory Perugino¹¹, ¹University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ²Ragon Institute of Mass General Brigham, MIT, and Harvard, Boston, ³Montgomery Blair High School, Brigham and Women’s Hospital, Boston, ⁴Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Ragon Institute of MGH, MIT and Harvard/ Royal Prince Alfred Hospital Sydney, Sydney, Australia, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Harvard Medical School, Cambridge, MA, ¹¹Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease typified by mass-forming lesions. Self-antigens driving the oligoclonal expansion of plasmablasts have previously been reported. However,…
Abstract Number: 0617 • ACR Convergence 2025
Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
Kathryn Counts¹, Dulaney Wilson², Leon Furchtgott³ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³SeraNova Bio, Boston, MA
Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…
Abstract Number: 2386 • ACR Convergence 2025
Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
Braden Zeno¹, Shane Bruckner², kassidy Banford³, Hannah Bulgart⁴, Stacy Ardoin⁵, noah weisleder⁴ and Wael Jarjour⁶, ¹Ohio State University, upper arlington, OH, ²OSU, Columbus, OH, ³Loyola University Chicago, Columbus, OH, ⁴University of Kentucky, Lexington, KY, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation in many of the body’s tissues, including the heart. Recent studies attribute…
Abstract Number: 0888 • ACR Convergence 2025
TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Adam S. Weinheimer¹, Olivia Pryor², Catalina Burbano³, Tyler Heath³, Livio Dukaj³, Shoshana M.K. Bloom³, Jackson Lirette³, Rachel Lent³, Prachi Dhanania³, Nicole A. Ladd³, Ryan Kritzer³, Hana Husic³, Shobitha Jillella³, Alexander Cristofaro², Chandan K. Pavuluri³, Jenna LaBelle³, Laurie Barefoot³, Shrikanta Chattopadhyay³, Andrew P. Ferretti³ and Cagan Gurer³, ¹TScan Therapeutics, Boston, MA, ²TScan Therapeutics, Waltham, ³TScan Therapeutics, Waltham, MA
Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing…
Abstract Number: 2027 • ACR Convergence 2025
Development of a multi-disease panel for autoimmune diseases
Charlotta Preger, Maria Aspenberg, Metta Berenpas, Peter Nilsson and Elisa Pin, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].